Postprocedural Optimal Medical Therapy Composite Medical therapy, including aspirin, P2Y12 inhibitors, and statins, has been proved to reduce all-cause mortality and car- diovascular morbidity in multiple studies. These medications should be prescribed to all patients who are eligible for them after PCI, except for the rare circumstances in which the life expectancy of the patient is limited or the patient has a known allergy or intolerance. Despite the strong endorsement from the guidelines and their robust evidence base, the use of these medications is less than optimal, particularly for statin therapy. Recently, Borden and colleagues36 evaluated the use of opti- mal medical therapy in patients undergoing PCI for stable dis- ease who were enrolled in the National Cardiovascular Data Registry CathPCI Registry. Statins were prescribed to 83% of patients who were discharged alive after PCI, after exclusion of patients with a contraindication to or history of intolerance of statins. Thus, opportunity remains for substantial improve- ment in the use of these medications in patients undergoing Incorporating these medications into the standard post- PCI order sets and having a detailed discussion of their benefits can be very effective at ensuring patient adherence, particularly with statin therapy.37 This measure harmonizes closely with the corresponding facility-level postprocedural optimal medical therapy composite measure from the ACC.38 5.8. Cardiac Rehabilitation Patient Referral Cardiac rehabilitation is a multidisciplinary exercise-based out- patient service that has been proved to provide patient benefit in terms of improved functional status, quality of life, medi- cal resource use, and, ultimately, mortality rate reduction.39 46 Patients with coronary artery disease treated with PCI are at high risk of recurrent events and are particularly suitable for risk reduction via cardiac rehabilitation. 